35 Recruiting Metastatic Urothelial Carcinoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Metastatic Urothelial Carcinoma
Related Conditions
Top Recruiting Metastatic Urothelial Carcinoma Studies
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
📍 Moores Cancer Center ( Site 3028) — La Jolla, California
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
📍 University of California San Francisco HDFCCC ( Site 4044) — San Francisco, California
View Study & Checklist ➔